Spinal Disease Information Centre, University Hospital of Glostrup, Denmark.
Acta Neurochir (Wien). 2010 Dec;152(12):2125-32. doi: 10.1007/s00701-010-0840-1. Epub 2010 Oct 16.
The study aims to assess the efficacy and safety of surgical treatment of trigeminal neuralgia (TN) in our department and to identify prognostic factors.
Seventy patients receiving surgical treatment for TN during the period 2003-2004 were included in this retrospective study. The surgical procedures used were glycerol injection (GI), microvascular decompression (MVD), or rhizotomia (RIZ). All patients were divided into spontaneous onset TN type1 (brief lancinating pain) or TN type 2 (continuous pain component). Two patients had bilateral TN; each side was regarded as a separate case. These 70 patients had a total of 160 interventions (110 GI, 40 MVD, and ten RIZ) performed in the period 1998-2007. Data were obtained by chart review and telephone interview. Patients provided information about pre- and postoperative pain characteristics including subtype, duration, intensity, and the use of antiepileptic drugs. Outcome was evaluated using a pain vector diagram.
To quantify self-reported pain, we developed a new vector-based pain diagram. The subtype of TN was shown to be a very important prognostic factor. One year after MVD, 90% of patients with type 1 TN still had positive effect, whereas this was only true in 73% of patients with type 2 TN. After RIZ, the results were 71% and 33% for types 1 and 2, respectively. For comparison, GI had a significant lower effect but if the treatment led to hypoesthesia, 41% continued to have a positive effect 1 year after surgery, compared to only 24% if postoperative sensation was normal. Type 2 TN was found to be dominated by women with left-sided TN outside the V2 dermatome and with a lower probability of a neurovascular conflict. As expected, 1/5 of the cases developed postoperative hypoesthesia in the face following a nerve destructive procedure (RIZ and GI). Using MVD, the risk of serious side effects was about 4%. Complementary and alternative treatment had no general or permanent effect in the investigated population-quite the contrary.
Regarding prognosis and outcome, we find that it is very important to classify TN in subgroups (types 1 and 2). Dealing with medically treatment-resistant type 1 TN, MVD and RIZ are reasonably safe and effective interventions. The surgical results dealing with type 2 TN are still very poor. All patients with medically treatment-resistant TN should be offered referral to a neurosurgical unit with experience in treating this painful disease. We recommend using a vector-based pain diagram when evaluating the outcome of multiple interventions.
本研究旨在评估我科三叉神经痛(TN)手术治疗的疗效和安全性,并确定预后因素。
本回顾性研究纳入了 2003-2004 年期间接受手术治疗的 70 例 TN 患者。所用手术方式为甘油注射(GI)、微血管减压术(MVD)或神经根切断术(RIZ)。所有患者分为原发性 TN 1 型(短暂刺痛)或 TN 2 型(持续性疼痛成分)。有 2 例患者为双侧 TN,每侧视为单独病例。1998-2007 年期间共进行了 70 例患者的 160 次干预(110 次 GI、40 次 MVD 和 10 次 RIZ)。通过图表回顾和电话访谈获取数据。患者提供了术前和术后疼痛特征的信息,包括亚型、持续时间、强度和抗癫痫药物的使用情况。使用疼痛向量图评估结果。
为了量化自我报告的疼痛,我们开发了一种新的基于向量的疼痛图。TN 的亚型是一个非常重要的预后因素。MVD 治疗后 1 年,90%的 1 型 TN 患者仍有阳性效果,而 2 型 TN 患者仅为 73%。RIZ 治疗后,1 型和 2 型的结果分别为 71%和 33%。相比之下,GI 的效果明显较低,但如果治疗导致感觉迟钝,术后 1 年仍有 41%的患者有阳性效果,而术后感觉正常的患者只有 24%。2 型 TN 主要为女性,左侧 TN 位于 V2 皮节以外,且发生神经血管冲突的可能性较低。正如预期的那样,在神经破坏性手术(RIZ 和 GI)后,有 1/5 的病例面部出现术后感觉迟钝。使用 MVD,严重副作用的风险约为 4%。在研究人群中,补充和替代治疗没有普遍或永久的效果——恰恰相反。
就预后和结果而言,我们发现将 TN 分为亚组(1 型和 2 型)非常重要。对于药物治疗抵抗的 1 型 TN,MVD 和 RIZ 是合理安全且有效的干预措施。处理 2 型 TN 的手术结果仍然很差。所有药物治疗抵抗的 TN 患者均应转介至具有治疗这种疼痛疾病经验的神经外科单位。我们建议在评估多次干预的结果时使用基于向量的疼痛图。